| Document |
Document Title |
|
WO/2014/202493A1 |
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, di...
|
|
WO/2014/204861A1 |
The present invention provides a compound having the adenosylmethionine structure, wherein the sulfur atom of the methionine moiety is modified with alkene or succinimide groups, wherein R1, R2 and R3 are independently H, alkyl, aryl, C(...
|
|
WO/2014/169280A3 |
Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure Formula (I) The variables, e.g., B1, Y, R1, R2, R3, R3', R4, R5, R6, R7, R8, and R9 carry definitions set fort...
|
|
WO/2014/194826A1 |
The present invention provides a three-circle fused-heterocycle nucleoside phosphoramidate compound, a preparation method therefor, a composition containing the fused-heterocycle nucleoside phosphoramidate compound, and an application of...
|
|
WO/2014/197578A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/159669A3 |
Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided.
|
|
WO/2014/193663A1 |
The present disclosure relates to 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives as inhibitors of HCV replicon RNA replication. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use ...
|
|
WO/2014/160200A9 |
Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or pre...
|
|
WO/2014/186637A1 |
The present disclosure relates to 4'-fluoro-2'-methyl substitured nucleoside derivatives, pharmaceutical compositions thereof, and methods of using such compounds and/or compositions thereof, for the treatment of HCV.
|
|
WO/2014/183462A1 |
The present invention relates to phosphoric acid/phosphonic acid derivatives shown by formula (I), wherein R1 and R2 represent the following structures: (Q1), or (Q2), or (Q3). Q1 represents ester derivatives of L-amino acids, wherein R3...
|
|
WO/2014/177119A1 |
A new polymorph of 2-[4-[(methylamino)carbonyl]-1 H-pyrazol-1- yl]adenosine (designated as polymorph E), of formula I, characterized by an X-ray diffraction pattern of X-RPD showing the following reflections at 2 Theta = 5.8°, 12.3°, 1...
|
|
WO/2014/178082A1 |
The present invention provides novel chiral serinyl functionalized tethered oligonucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a...
|
|
WO/2014/179760A1 |
Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2'-5' phosphodiester linkage comprising cyclic-di-nucleotide in a cell i...
|
|
WO/2014/059275A3 |
The present invention relates to novel strains of Streptomyces microflavus and methods of their use for controlling diseases or pests of a plant. The invention also relates to a fermentation broth obtained by cultivating a gougerotin pro...
|
|
WO/2014/175836A1 |
This invention relates to a nucleic acid nanoparticle comprising at least one G-quadruplex structure wherein at least one guanine base comprises a modification in the N2-position and the use of said nucleic acid nanoparticle as a medicam...
|
|
WO/2014/172330A1 |
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
|
|
WO/2014/167046A1 |
A process for the preparation of the amorphous form of Regadenoson of formula (I) is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mi...
|
|
WO/2014/169278A1 |
A deuterated nucleoside analog of the formula and the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a ...
|
|
WO/2014/169280A2 |
Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure Formula (I) The variables, e.g., B1, Y, R1, R2, R3, R3', R4, R5, R6, R7, R8, and R9 carry definitions set fort...
|
|
WO/2014/130686A3 |
Provided herein are nanostructure-based sequencing methods and systems.
|
|
WO/2014/165542A1 |
Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2',4'-fluo...
|
|
WO/2014/160484A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/160698A1 |
Provided herein are solid forms comprising (a) 4-amino-l-β-D-ribofuranosyl-1,3,5-triazin-2(1 H)-one (known as 5-azacytidine) and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for t...
|
|
WO/2014/154921A1 |
The invention relates to the method for the synthesis of homologous compounds of azanucleosides, to the compounds produced by said method, and to the use of same for developing drugs for treating viral and bacterial diseases and cancer.
|
|
WO/2014/160502A1 |
This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders ...
|
|
WO/2014/160200A1 |
Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or pre...
|
|
WO/2014/157565A1 |
Provided are a new photoreactive compound which is usable in a technique of photoreaction of nucleic acids and a photoreactive crosslinking agent which comprises the photoreactive compound. This photoreactive compound is represented by f...
|
|
WO/2014/152733A1 |
Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amoun...
|
|
WO/2014/148928A1 |
The present invention is the method for incorporation of acetal and acetal ester groups for protection of hydroxyl function. The method is applied in particular in the processes of RNA synthesis. The method can be employed in the synthes...
|
|
WO/2014/150851A1 |
Provided herein is technology relating to sequencing nucleic acids, but not exclusively, to compositions, methods, systems, and kits related to nucleotides comprising an electrochemically detectable moiety and one or more photolabile syn...
|
|
WO/2014/152723A1 |
The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applie...
|
|
WO/2014/145207A1 |
In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods...
|
|
WO/2014/143051A1 |
Fluorinated pyrimidine analog compounds, compositions that include the fluorinated pyrimidine analog compounds, methods for making the fluorinated pyrimidine analog compounds, and methods for inhibiting DNA methyltransferase, treating so...
|
|
WO/2014/139596A1 |
Some embodiments described herein relate to modified nucleotide and nucleoside molecules with novel 3'-hydroxy protecting groups. Said 3'-hydroxy protecting groups form a structure -O-C(R)2N3 covalently attached to the 3'-carbon atom whe...
|
|
WO/2014/140348A1 |
The present invention provides fluorine substituted tricyclic nucleosides of formula (I) wherein: the substituents are as defined in the claims. The present invention further provides oligomeric compounds prepared therefrom. Incorporatio...
|
|
WO/2014/137930A1 |
Provided herein are compounds, compositions, and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001; where PD, Base, RA and RB are as provid...
|
|
WO/2014/137926A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/135107A1 |
Provided are a novel nucleoside phosphoramidate compound, stereoisomer, salt, hydrate, solvate or crystal thereof for treating flaviviridae virus, in particular a hepatitis C virus infection. Also provided are a pharmaceutical compositio...
|
|
WO/2014/134251A1 |
Described herein are compositions that can include Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds. Also, described herein is a method of treating a HCV infection in a subject tha...
|
|
WO/2014/131892A1 |
The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2' position to comprise the structure of formula (I), wherein base is a pur...
|
|
WO/2014/126229A1 |
The present invention provides a novel nucleoside or nucleotide usable as a material for the synthesis of a nucleic acid medicine, particularly, a compound represented by formula (I) or a salt thereof [wherein: Y1 is CR6 or N; Y2 is CR7 ...
|
|
WO/2014/116755A1 |
The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or canc...
|
|
WO/2014/112463A1 |
The invention provides compounds shown by the formula (in the formula Y1-Y2 is S(=O)2-NR6, NR6-S(=O)2, or the like; R6 is a hydrogen atom, substituted or unsubstituted alkyl group, or the like; Bx is a nucleic acid base moiety; Z1 and Z2...
|
|
WO/2014/113609A1 |
Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indo...
|
|
WO/2014/109256A1 |
Provided is a means for improving the chemical stability and lipid solubility of an artificial cyclic nucleoside linked body, which is an analogue of a naturally-occurring-type cyclic dinucleotide, while keeping the structural similarity...
|
|
WO/2014/109384A1 |
The present invention provides a method for producing an amide cross-linked nucleic acid derivative, which is useful as a molecule for use as an antisense, with high efficiency. An intermediate that is important for the synthesis of an a...
|
|
WO/2014/068589A3 |
The present invention relates to a novel process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}
pyrazole-4-yl)-N-methylcarboxamide.
|
|
WO/2014/060941A3 |
Disclosed are compounds of formula I, their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of...
|
|
WO/2014/103704A1 |
A method for producing P1,P4-di(uridine 5'-)tetraphosphate (UP4U) is developed, which does not require the use of free UTP and does not undergo the decrease in synthesis efficiency. A method for producing UP4U, characterized by reacting ...
|
|
WO/2014/100498A1 |
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
|
